Endocrinol Metab > Volume 27(1); 2012 > Article
Endocrinology and Metabolism 2012;27(1):68-71.
DOI: https://doi.org/10.3803/EnM.2012.27.1.68    Published online March 1, 2012.
A Case of Sunitinib-Induced Destructive Thyroiditis.
Bu Kyung Kim, Young Sik Choi, Yo Han Park
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. yschoi@kosinmed.or.kr
Sunitinib is a multi-targeted tyrosine-kinase inhibitor used for gastrointestinal stromal tumors and renal cell carcinoma (RCC). Several recent studies have reported sunitinib-induced hypothyroidism and thyroid dysfunction; however, the underlying mechanisms are not clear. Here, we report a patient with metastatic RCC, who developed destructive thyroidtis due to sunitinib treatment. The course followed in this case may be useful in understanding the clinical course of sunitinib-induced thyroiditis.
Key Words: Destructive thyroiditis, Sunitinib

Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2022 by Korean Endocrine Society.

Developed in M2PI